There are represented sclerostin binding sequences or amino acid sequences determining segments complementarity in (CDR) antibodies blocking binding and isolated coding polynucleotide sequences thereof, pharmaceutical compositions containing said antibodies and their usage at the treatment of diseases associated with sclerostin, particularly, with bone mineralization related diseases.
